Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

Presentation AHA 2017

Insights from the FOURIER Trial

Presenter: Marc P. Bonaca

November 15, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

Shelley Wood

November 09, 2017

Presentation TCT 2017

FOURIER Trial: Topline Findings and Practice Implications

Presenter: Robert A. Harrington, Evan A. Stein, Wolfgang Koenig

November 01, 2017

Presentation TCT 2017

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Michael O'Riordan

October 10, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

Biomedical Research in CVD: More Investment Today Will Yield Long-term Rewards

Caitlin E. Cox

June 29, 2017

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Insights from the FOURIER Trial

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

FOURIER Trial: Topline Findings and Practice Implications

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

ESC Updates Guidelines for Treating STEMI Patients

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Evolocumab Not Cost-Effective at Current List Price

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Biomedical Research in CVD: More Investment Today Will Yield Long-term Rewards

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content